Suggestion de sujets dans votre recherche.
Résultat(s) 1 - 9 résultats de 9 pour la requête '', Temps de recherche: 2,91s Affiner les résultats
  1. 1
    Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation A proof of concept

    Article en ligne

  2. 2
    Cellular changes in eculizumab early responders with generalized myasthenia gravis

    Article en ligne

  3. 3
    Complement C3 vs C5 inhibition in severe COVID-19 Early clinical findings reveal differential biological efficacy

    Article en ligne

  4. 4
    Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

    Article en ligne

  5. 5
    Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss

    Article en ligne

  6. 6
    Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration
    Article en ligne

  7. 7
    Intravenous immunoglobulin attenuates mesenteric ischemia-reperfusion injury
    Article

  8. 8
    C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury
    Article

  9. 9
    C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion
    Article

Outils de recherche: S'abonner aux flux RSS — Envoyer cette recherche par courriel